Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
P/B ratio for Mind Medicine (MindMed) Inc. (MNMD)
P/B ratio as of 2023: 1.83
According to Mind Medicine (MindMed) Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.83. At the end of 2022 the company had a P/B ratio of 0.45.
P/B ratio history for Mind Medicine (MindMed) Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.83 |
| 2022 | 0.45 |
| 2021 | 3.74 |
| 2020 | 10.70 |
| 2019 | 0.10 |
| 2018 | 0.13 |
| 2017 | 0.36 |
| 2016 | 2.14 |
| 2015 | 0.94 |